UBS Oconnor LLC bought a new stake in Exact Sciences Corporation (NASDAQ:EXAS) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 59,671 shares of the medical research company’s stock, valued at approximately $2,111,000. UBS Oconnor LLC owned about 0.05% of Exact Sciences Corporation as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of EXAS. Fortaleza Asset Management Inc. acquired a new position in shares of Exact Sciences Corporation during the second quarter valued at $106,000. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Exact Sciences Corporation by 17.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 4,072 shares of the medical research company’s stock valued at $144,000 after buying an additional 600 shares during the last quarter. Financial Architects Inc raised its holdings in shares of Exact Sciences Corporation by 90.0% during the second quarter. Financial Architects Inc now owns 4,295 shares of the medical research company’s stock valued at $152,000 after buying an additional 2,035 shares during the last quarter. Johnson Financial Group Inc. raised its holdings in shares of Exact Sciences Corporation by 25.9% during the second quarter. Johnson Financial Group Inc. now owns 4,862 shares of the medical research company’s stock valued at $172,000 after buying an additional 1,000 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Exact Sciences Corporation by 66.2% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,052 shares of the medical research company’s stock valued at $179,000 after buying an additional 2,013 shares during the last quarter. Institutional investors own 85.23% of the company’s stock.

A number of equities research analysts recently weighed in on the stock. BidaskClub upgraded shares of Exact Sciences Corporation from a “hold” rating to a “buy” rating in a research note on Thursday, June 22nd. Leerink Swann set a $45.00 target price on shares of Exact Sciences Corporation and gave the stock a “buy” rating in a report on Thursday, August 24th. Vetr upgraded shares of Exact Sciences Corporation from a “buy” rating to a “strong-buy” rating and set a $36.39 target price for the company in a report on Tuesday, June 13th. Zacks Investment Research upgraded shares of Exact Sciences Corporation from a “hold” rating to a “buy” rating and set a $51.00 price target on the stock in a research report on Tuesday, September 26th. Finally, Canaccord Genuity reduced their price objective on Exact Sciences Corporation from $40.00 to $38.00 and set a “buy” rating for the company in a research note on Friday, June 9th. Five equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Buy” and an average price target of $42.11.

Exact Sciences Corporation (NASDAQ EXAS) traded up 0.5422% during trading on Monday, reaching $47.3755. The company’s stock had a trading volume of 258,601 shares. The company’s 50 day moving average price is $40.21 and its 200-day moving average price is $32.94. The stock’s market cap is $5.64 billion. Exact Sciences Corporation has a 1-year low of $13.05 and a 1-year high of $47.56.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its quarterly earnings results on Tuesday, July 25th. The medical research company reported ($0.27) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.10. Exact Sciences Corporation had a negative net margin of 83.08% and a negative return on equity of 36.36%. The company had revenue of $57.65 million for the quarter, compared to analyst estimates of $47.73 million. Equities analysts forecast that Exact Sciences Corporation will post ($1.18) earnings per share for the current fiscal year.

In related news, Director Thomas D. Carey bought 2,500 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were purchased at an average cost of $37.71 per share, for a total transaction of $94,275.00. Following the completion of the purchase, the director now directly owns 60,858 shares in the company, valued at $2,294,955.18. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Jeffrey Thomas Elliott sold 5,846 shares of the stock in a transaction that occurred on Monday, July 31st. The shares were sold at an average price of $39.41, for a total transaction of $230,390.86. Following the transaction, the chief financial officer now directly owns 19,861 shares of the company’s stock, valued at $782,722.01. The disclosure for this sale can be found here. Over the last quarter, insiders sold 127,304 shares of company stock worth $5,218,219. 4.00% of the stock is owned by company insiders.

ILLEGAL ACTIVITY WARNING: “UBS Oconnor LLC Buys Shares of 59,671 Exact Sciences Corporation (EXAS)” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/02/ubs-oconnor-llc-buys-shares-of-59671-exact-sciences-corporation-exas.html.

About Exact Sciences Corporation

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Stock Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related stocks with our FREE daily email newsletter.